Windtree Therapeutics Stock Fundamentals
| WINT Stock | USD 0.02 0.00 0.00% |
Windtree Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Windtree Stock price.
At this time, Windtree Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 28.7 M in 2026, whereas Gross Profit is likely to drop (101.4 K) in 2026. Windtree | Select Account or Indicator | Build AI portfolio with Windtree Stock |
Windtree Therapeutics Company Number Of Shares Shorted Analysis
Windtree Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Windtree Therapeutics Number Of Shares Shorted | 1.79 M |
Most of Windtree Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Windtree Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Windtree Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Windtree Therapeutics is extremely important. It helps to project a fair market value of Windtree Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Windtree Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Windtree Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Windtree Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Windtree Therapeutics has 1.79 M of outstending shares currently sold short by investors. This is 44.03% lower than that of the Biotechnology sector and 64.87% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 61.95% higher than that of the company.
Windtree Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Windtree Therapeutics's current stock value. Our valuation model uses many indicators to compare Windtree Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Windtree Therapeutics competition to find correlations between indicators driving Windtree Therapeutics's intrinsic value. More Info.Windtree Therapeutics is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Windtree Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Windtree Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Windtree Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.Windtree Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Windtree Fundamentals
| Return On Equity | -4.13 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 13.4 M | ||||
| Shares Outstanding | 33.63 M | ||||
| Shares Owned By Institutions | 0.07 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (1.47 M) | ||||
| Net Income | (1.79 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 1.82 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (15.4 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | 62.60 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 27.88 M | ||||
| Retained Earnings | (846.61 M) | ||||
| Working Capital | (3.14 M) | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
| Net Asset | 27.88 M |
About Windtree Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 178.2 K | 169.3 K | |
| Cost Of Revenue | 75.6 K | 71.8 K | |
| Stock Based Compensation To Revenue | 39.04 | 37.08 | |
| Sales General And Administrative To Revenue | 72.04 | 75.65 | |
| Research And Ddevelopement To Revenue | 57.67 | 60.55 | |
| Capex To Revenue | 0.87 | 0.90 | |
| Revenue Per Share | 937.64 | 890.76 | |
| Ebit Per Revenue | (144.58) | (137.35) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.